Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 1998 Jun;113(Suppl 1):182–188.

Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done.

D C Des Jarlais 1, S R Friedman 1
PMCID: PMC1307740  PMID: 9722823

Abstract

OBJECTIVE: Acquired immunodeficiency syndrome (AIDS) was formally identified among injecting drug users (IDUs) in 1981, and research on preventing human immunodeficiency virus (HIV) infection among drug injectors began shortly thereafter. At the time this research was begun, there was a general assumption that drug user (who were called drug abusers at that time) were too self-destructive and their behavior too chaotic for them to change their behavior to avoid infection with HIV. This chapter reviews the history of research on implementation of programs for prevention of HIV infection among IDUs. METHODS: Reviews of both research and program implementation research were conducted. Consultative discussions of issues and findings were conducted with researcher in the United States and other countries. RESULTS: An extremely large amount of useful information has accumulated during the pat 15 years. We now know that the great majority of IDUs will change their injecting behavior in response to the threat of AIDS and that these behavior changes are effective in reducing HIV transmission among drug injectors. Additional insight is needed regarding the apparent insufficiency of some prevention programs to control HIV, the transmission dynamics of rapid HIV spread, and the persistence of moderate to high incidence of HIV infection in high seroprevalence populations. Despite the current research knowledge base, implementation of effective prevention programs in may countries is nonexistent to incomplete. CONCLUSIONS: The most important barrier to reducing HIV transmission among drug injectors is not a lack of knowledge but the failure to implement effective prevention programs in may parts of the world.

Full text

PDF
182

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Des Jarlais D. C., Friedman S. R., Choopanya K., Vanichseni S., Ward T. P. International epidemiology of HIV and AIDS among injecting drug users. AIDS. 1992 Oct;6(10):1053–1068. doi: 10.1097/00002030-199210000-00001. [DOI] [PubMed] [Google Scholar]
  2. Des Jarlais D. C., Friedman S. R., Novick D. M., Sotheran J. L., Thomas P., Yancovitz S. R., Mildvan D., Weber J., Kreek M. J., Maslansky R. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989 Feb 17;261(7):1008–1012. doi: 10.1001/jama.261.7.1008. [DOI] [PubMed] [Google Scholar]
  3. Des Jarlais D. C., Friedman S. R., Ward T. P. Harm reduction: a public health response to the AIDS epidemic among injecting drug users. Annu Rev Public Health. 1993;14:413–450. doi: 10.1146/annurev.pu.14.050193.002213. [DOI] [PubMed] [Google Scholar]
  4. Des Jarlais D. C., Friedmann P., Hagan H., Friedman S. R. The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. Am J Public Health. 1996 Dec;86(12):1780–1785. doi: 10.2105/ajph.86.12.1780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Des Jarlais D. C., Hagan H., Friedman S. R., Friedmann P., Goldberg D., Frischer M., Green S., Tunving K., Ljungberg B., Wodak A. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995 Oct 18;274(15):1226–1231. doi: 10.1001/jama.274.15.1226. [DOI] [PubMed] [Google Scholar]
  6. Des Jarlais D. C., Marmor M., Paone D., Titus S., Shi Q., Perlis T., Jose B., Friedman S. R. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996 Oct 12;348(9033):987–991. doi: 10.1016/s0140-6736(96)02536-6. [DOI] [PubMed] [Google Scholar]
  7. Des Jarlais D. C. The first and second decades of AIDS among injecting drug users. Br J Addict. 1992 Mar;87(3):347–353. doi: 10.1111/j.1360-0443.1992.tb01935.x. [DOI] [PubMed] [Google Scholar]
  8. Friedman S. R., Des Jarlais D. C. HIV among drug injectors: the epidemic and the response. AIDS Care. 1991;3(3):239–250. doi: 10.1080/09540129108253069. [DOI] [PubMed] [Google Scholar]
  9. Friedman S. R., Des Jarlais D. C., Sotheran J. L., Garber J., Cohen H., Smith D. AIDS and self-organization among intravenous drug users. Int J Addict. 1987 Mar;22(3):201–219. doi: 10.3109/10826088709027425. [DOI] [PubMed] [Google Scholar]
  10. Friedman S. R., Jose B., Deren S., Des Jarlais D. C., Neaigus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. Am J Epidemiol. 1995 Oct 15;142(8):864–874. doi: 10.1093/oxfordjournals.aje.a117726. [DOI] [PubMed] [Google Scholar]
  11. Hagan H., Des Jarlais D. C., Purchase D., Friedman S. R., Reid T., Bell T. A. An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction. 1993 Dec;88(12):1691–1697. doi: 10.1111/j.1360-0443.1993.tb02044.x. [DOI] [PubMed] [Google Scholar]
  12. Holmberg S. D. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996 May;86(5):642–654. doi: 10.2105/ajph.86.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Masur H., Michelis M. A., Greene J. B., Onorato I., Stouwe R. A., Holzman R. S., Wormser G., Brettman L., Lange M., Murray H. W. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981 Dec 10;305(24):1431–1438. doi: 10.1056/NEJM198112103052402. [DOI] [PubMed] [Google Scholar]
  14. Metzger D. S., Woody G. E., McLellan A. T., O'Brien C. P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993 Sep;6(9):1049–1056. [PubMed] [Google Scholar]
  15. Naik T. N., Sarkar S., Singh H. L., Bhunia S. C., Singh Y. I., Singh P. K., Pal S. C. Intravenous drug users--a new high-risk group for HIV infection in India. AIDS. 1991 Jan;5(1):117–118. doi: 10.1097/00002030-199101000-00026. [DOI] [PubMed] [Google Scholar]
  16. Orr M. F., Glebatis D., Friedmann P., des Jarlais D. C., Prevots D. R. Incidence of HIV infection in a New York City methadone maintenance treatment program. JAMA. 1996 Jul 10;276(2):99–99. doi: 10.1001/jama.276.2.99b. [DOI] [PubMed] [Google Scholar]
  17. Robertson J. R., Bucknall A. B., Welsby P. D., Roberts J. J., Inglis J. M., Peutherer J. F., Brettle R. P. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):527–529. doi: 10.1136/bmj.292.6519.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Strathdee S. A., Patrick D. M., Currie S. L., Cornelisse P. G., Rekart M. L., Montaner J. S., Schechter M. T., O'Shaughnessy M. V. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997 Jul;11(8):F59–F65. doi: 10.1097/00002030-199708000-00001. [DOI] [PubMed] [Google Scholar]
  19. van Ameijden E. J., van den Hoek J. A., van Haastrecht H. J., Coutinho R. A. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. Am J Epidemiol. 1992 Jul 15;136(2):236–243. doi: 10.1093/oxfordjournals.aje.a116489. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES